A Trial to Evaluate the Combination of Iressa & Faslodex® in Patients With Advanced or Metastatic Breast Cancer
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
The progression free survival and efficacy of 250 mg ZD1839 in combination with a fixed dose
of fulvestrant 250 mg im once a month will be evaluated in female patients with
histologically-confirmed advanced or metastatic, ER and/or PR positive breast cancer